Latest News for AIM
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combination with the PD-1 checkpoint inhibitor pembrolizumab for the treatment of cancer.
Lions Bay Resources has rejected a claim by Vantage Goldfields that its proposed acquisition of the Barbrook gold mine in South Africa has failed, describing the statement as false and misleading. The company is owned by Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the AIM-listed mining company, and Lions Bay Capital, which trades on the TSX Venture Exchange.
Video webcast now available here
Shares in Alien Metals Ltd (AIM:UFO, OTC:ASLRF), the AIM-listed minerals exploration and development company, rose 4% to 0.10p on Thursday. The move followed diamond drilling results from the Elizabeth Hill Silver Project in Western Australia, announced by joint venture partner West Coast Silver, which is listed on the Australian Securities Exchange.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AIM.
U.S. House Trading
No House trades found for AIM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.